Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
30 hedge funds and large institutions have $26M invested in Zynerba Pharmaceuticals, Inc in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
5% less capital invested
Capital invested by funds: $27.2M → $26M (-$1.26M)
3% less funds holding
Funds holding: 31 → 30 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.11M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$955K |
| 4 |
AAM
Auxier Asset Management
Aurora,
Oregon
|
+$264K |
| 5 |
Two Sigma Investments
New York
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.53M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$564K |
| 3 |
NC
Nexthera Capital
New York
|
-$151K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$43K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$41.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $3K | +$1.99K | +247 | +231% |
|
|
IA
27
IFP Advisors
Tampa,
Florida
| $3K | +$4.03K | +500 | New |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
29
BNP Paribas Financial Markets
Paris,
France
| $539 | -$4.7K | -583 | -91% |
|
30
Geode Capital Management
Boston,
Massachusetts
| $140 | -$202 | -25 | -0.2% |
|
|
31
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$4.53M | -450,000 | Closed |
|
|
NC
32
Nexthera Capital
New York
| – | -$151K | -15,000 | Closed |
|
|
33
UBS Group
Zurich,
Switzerland
| – | -$43K | -4,311 | Closed |
|
|
CCA
34
Catalyst Capital Advisors
Huntington,
New York
| – | -$4K | -348 | Closed |
|
35
Bank of America
Charlotte,
North Carolina
| – | -$1K | -83 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$1K | -62 | Closed |
|
ZYNE Hedge Fund Activity: Q1 2016 in Review
30 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2016, worth a combined $26M — down 4.6% from $27.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ZYNE and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 10 added.
The largest buyer was Perceptive Advisors, adding an estimated $2.35M. The largest seller was Federated Hermes, exiting entirely with an estimated $4.53M sold.
- 30 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2016, down from 31 in Q4 2015.
- Funds reported $26M of Zynerba Pharmaceuticals, Inc stock for Q1 2016, down 4.6% quarter-over-quarter.
- 5 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2016 and 6 closed out, a net change of -1 holder.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2016 was Perceptive Advisors, an estimated $2.35M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2016 was Federated Hermes, an estimated $4.53M sold.
Based on aggregated 13F filings for Q1 2016.